

Prenatal care is necessary to ensure a healthy pregnancy and successful childbirth. Early prenatal screenings identify potential health concerns and guide medical interventions when necessary. The Double Marker Test- First Trimester is essential for early prenatal assessment. It offers invaluable insights into the developing fetus's chromosomal health. The test primarily measures two important biomarkers in the mother’s blood—human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein A (PAPP-A). Both the markers are produced by the fetus and the placenta.
The test also checks if the baby might be at risk for certain genetic problems, especially Down syndrome and Edwards syndrome. These conditions happen when there is an extra copy of chromosome 21 or 18, respectively. They can affect a baby's physical and intellectual development. However, a Double Marker Test-First Trimester is a screening test, not a diagnostic one. It does not determine whether the baby has abnormalities. Instead, it tells whether the unborn baby is at risk of developing certain abnormalities.
The test results are reported as a risk score or probability of the fetus having a chromosomal abnormality. Test results within the expected range suggest a lower risk of chromosomal abnormalities. On the contrary, high levels may indicate a higher risk of chromosomal abnormalities and prompt further testing. Furthermore, a positive screen result (high risk) does not confirm a genetic problem. It may suggest that further testing may be needed to check the baby's health more closely. On the other hand, a negative screen result (low risk) does not guarantee the absence of fetal defects.
In combined risk assessment, the NT scan (a type of ultrasound) is also used to check for conditions like Down syndrome and Patau syndrome. This, along with the mother’s details—such as age, weight, smoking, diabetes, or IVF pregnancy—is included in the overall risk calculation. However, this test does not check for neural tube defects.
No fasting is required for this test. For this test, a duly filled Maternal Serum Screen requisition form (Annexure - CR/02) and a doctor’s prescription are mandatory. Also, provide information like maternal date of birth, last date of the last menstrual period (LMP), number of fetuses (single/twins), diabetic status, body weight in kg, and history of IVF, smoking, and trisomy 21 pregnancy. It is mandatory to keep a hard copy of the latest pregnancy ultrasound report (date of scan, CRL, NT in mm/NB, Level 1) for combined risk assessment. The double marker test is valid between 9 and 13 weeks of gestation (the ideal time for combined risk assessment is between 10 and 13 weeks). Also, tell your doctor about the medications you are taking, as certain medications can affect the results of this test and might need to be discontinued.Talk to the doctor about the specific test results. The accuracy of the results is subjective to the information provided in the screening form. This information is mandatory for combined risk assessment.
The Double Marker Test- First Trimester measures two biomarkers in maternal blood associated with chromosomal abnormalities.
a) Free beta-hCG (human chorionic gonadotropin): a hormone made by the placenta shortly after a woman becomes pregnant.
b) PAPP-A (pregnancy-associated plasma protein-A): a protein made by the placenta during early pregnancy. It helps the placenta grow and function properly.
These, along with the USG marker and nuchal translucency (NT) measurement, are effective in Combined screening for Down syndrome and trisomy 13/18 in the fetus. This test only gives the risk for the presence of these chromosomal abnormalities in the developing fetus. A positive screen is not diagnostic but indicates that further evaluation should be considered.
hCG is synthesized by the placenta very early in pregnancy and can be detected in the blood 8-11 days after conception. Higher levels of hCG after 11 weeks of gestation may suggest a higher chance of the baby having Down syndrome. On the other hand, low levels indicate an increased risk for trisomy 18.
PAPP-A is a protein produced by the placenta that is needed for the implantation and maintenance of a healthy placenta (afterbirth). Low levels of PAPP-A before the 14th week of pregnancy suggest an increased risk of fetal chromosomal abnormalities.
The Double Marker Test- First Trimester is done:
- For the early risk assessment of Down, Patau, and Edward syndromes in developing fetuses.
- In pregnant women above 35 years of age and those with a family history of birth defects and a history of insulin-dependent type 1 diabetes.
- A duly filled Maternal Serum Screen requisition form (Annexure - CR/02) and doctor's prescription are mandatory.
- Provide information like maternal date of birth (dd/mm/yy), last date of the last menstrual period (LMP), number of fetuses (single/twins), diabetic status, body weight in kg, and history of IVF, smoking, and Trisomy 21 pregnancy.
- Keep a hard copy of the latest pregnancy ultrasound report (Date of scan, CRL, NT in mm/NB, Level 1) - this is mandatory for combined risk assessment.
- The test is valid between 9 to 13 weeks of gestation (the ideal time for combined risk assessment is between 10 to 13 weeks).























